Abstract
The current modifications to licensing procedures still leave a basically flawed system in place. A more radical solution is proposed that involves dispensing with Phase 3 trials and making medicines available at the end of Phase 2 to those who are fully informed of the potential risks and benefits and wish to take part in this novel procedure. The advantages include a shorter development time, lower development costs and allowing smaller companies to take medicines to the clinic. The principal obstacle is that medicines are subject to strict liability rather than the tort of negligence – and this will have to be amended in due course.
Keywords: Phase 3, strict liability.
Reviews on Recent Clinical Trials
Title:A More Radical Solution
Volume: 10 Issue: 1
Author(s): Peter J. Lachmann
Affiliation:
Keywords: Phase 3, strict liability.
Abstract: The current modifications to licensing procedures still leave a basically flawed system in place. A more radical solution is proposed that involves dispensing with Phase 3 trials and making medicines available at the end of Phase 2 to those who are fully informed of the potential risks and benefits and wish to take part in this novel procedure. The advantages include a shorter development time, lower development costs and allowing smaller companies to take medicines to the clinic. The principal obstacle is that medicines are subject to strict liability rather than the tort of negligence – and this will have to be amended in due course.
Export Options
About this article
Cite this article as:
Lachmann J. Peter, A More Radical Solution, Reviews on Recent Clinical Trials 2015; 10 (1) . https://dx.doi.org/10.2174/1574887110666150430151051
DOI https://dx.doi.org/10.2174/1574887110666150430151051 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Current Vascular Pharmacology Joint ESC/EASD Guidelines on Diabetes, where are we Now and where should we Go?
Current Vascular Pharmacology Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Current Management of Peripheral Vascular Disease: Where is the Evidence?
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidative stress and myocarditis
Current Pharmaceutical Design Fibrinolytic Actinokinase-A Short Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders
Current Vascular Pharmacology Patent Selections:
Recent Patents on Medical Imaging Chemometric Assisted Simultaneous Analysis of Verapamil Hydrochloride, Gliclazide and Simvastatin in Bulk Drug and Fixed Dose Combinatinos (polypill) - A Futuristic Approach
Current Analytical Chemistry Serendipity of Erythromycin in the Management of Periprosthetic Inflammation
Current Drug Therapy ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Lifestyle Changes and Pharmacological Risk Factor Modification for Effective Vascular Disease Prevention
Vascular Disease Prevention (Discontinued) Human Endotoxemia as a Model of Systemic Inflammation
Current Medicinal Chemistry Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Effects of Ranolazine on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Relationship Between Hypertension and Atherosclerosis: From a Viewpoint of the Most Potent Vasoconstrictor Human Urotensin II
Current Hypertension Reviews MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges
Current Pharmaceutical Design Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Tuberculous Pericarditis
Current Cardiology Reviews